Company / SG&A per Share
Myriad Genetics, Inc. SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$3.16
FY2025
5-year range
$3.16 / $7.62
FY2021-FY2025
Trend
-8.3%
vs FY2024
Sector context
#58 of 210
Health Care
What the data says
At $3.16, Myriad Genetics, Inc.'s sg&a per share ranks #153 of 210 in the Health Care sector. SG&A per Share has fluctuated over the past 10 years, ranging from $3.16 in FY2025 to $7.62 in FY2021.
Based on SEC 10-K filings.
3.16 in FY2025 with a 5-year CAGR of -15.7%.
Improved from $7.60 to $3.16 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- -23.3%
- 5-Year CAGR
- -15.7%
- 10-Year CAGR
- -
Sector benchmark
#153 of 210 in Health CareTop 72% of 210This company $3.16 Sector average $29.50
▼
-89.3% below sector average
Key checks
Key Insights
- In FY2025, sg&a per share decreased 8.3% year-over-year.
- Ranks #58 out of 210 companies in the Health Care sector.
- Peak sg&a per share was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.23 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.16 | -8.3% |
| FY2024 | $3.45 | -54.6% |
| FY2023 | $7.60 | +8.5% |
| FY2022 | $7.00 | -8.1% |
| FY2021 | $7.62 | +2.7% |
| FY2020 | $7.42 | +16.5% |
| FY2019 | $6.37 | +0.8% |
| FY2018 | $6.31 | +5.5% |
| FY2017 | $5.99 | +34.3% |
| FY2016 | $4.46 | +0.6% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026